Jacquelyn Pence, Michelle Stockton, Richard J Bloomer
{"title":"膳食补充剂Cyplexinol®减轻了男性和女性的关节疼痛。","authors":"Jacquelyn Pence, Michelle Stockton, Richard J Bloomer","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study.</p><p><strong>Methods: </strong>We compared the impact of a dietary supplement protein complex (Cyplexinol<sup>®</sup>) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures.</p><p><strong>Results: </strong>Pain and discomfort scores improved (<i>P</i> ≤ 0.05) for subjects following use of Cyplexinol<sup>®</sup> but not placebo. Improvements were noted for WOMAC pain (<i>P</i> = 0.05), stiffness (<i>P</i> = 0.039), and total pain (<i>P</i> = 0.026), as well as VAS pain (<i>P</i> = 0.015), recreational activity interference (<i>P</i> = 0.023), mood interference (<i>P</i> = 0.012), and total pain (<i>P</i> = 0.024). A trend was noted for WOMAC physical function (<i>P</i> = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol<sup>®</sup> (<i>P</i> = 0.01), with a similar increase noted for placebo (<i>P</i> = 0.022). A near doubling in TGF-β (<i>P</i> = 0.001) was noted for Cyplexinol<sup>®</sup>. No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (<i>P</i> > 0.05).</p><p><strong>Conclusions: </strong>Cyplexinol<sup>®</sup> can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol<sup>®</sup> does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period.</p><p><strong>Relevance for patients: </strong>Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol<sup>®</sup>, as we observed decreased pain and stiffness following treatment.</p>","PeriodicalId":15482,"journal":{"name":"Journal of Clinical and Translational Research","volume":"9 3","pages":"212-221"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/2f/jclintranslres-2023-9-3-212.PMC10339409.pdf","citationCount":"0","resultStr":"{\"title\":\"The dietary supplement Cyplexinol<sup>®</sup> alleviates joint pain in men and women.\",\"authors\":\"Jacquelyn Pence, Michelle Stockton, Richard J Bloomer\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aim: </strong>Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study.</p><p><strong>Methods: </strong>We compared the impact of a dietary supplement protein complex (Cyplexinol<sup>®</sup>) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures.</p><p><strong>Results: </strong>Pain and discomfort scores improved (<i>P</i> ≤ 0.05) for subjects following use of Cyplexinol<sup>®</sup> but not placebo. Improvements were noted for WOMAC pain (<i>P</i> = 0.05), stiffness (<i>P</i> = 0.039), and total pain (<i>P</i> = 0.026), as well as VAS pain (<i>P</i> = 0.015), recreational activity interference (<i>P</i> = 0.023), mood interference (<i>P</i> = 0.012), and total pain (<i>P</i> = 0.024). A trend was noted for WOMAC physical function (<i>P</i> = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol<sup>®</sup> (<i>P</i> = 0.01), with a similar increase noted for placebo (<i>P</i> = 0.022). A near doubling in TGF-β (<i>P</i> = 0.001) was noted for Cyplexinol<sup>®</sup>. No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (<i>P</i> > 0.05).</p><p><strong>Conclusions: </strong>Cyplexinol<sup>®</sup> can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol<sup>®</sup> does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period.</p><p><strong>Relevance for patients: </strong>Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol<sup>®</sup>, as we observed decreased pain and stiffness following treatment.</p>\",\"PeriodicalId\":15482,\"journal\":{\"name\":\"Journal of Clinical and Translational Research\",\"volume\":\"9 3\",\"pages\":\"212-221\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/2f/jclintranslres-2023-9-3-212.PMC10339409.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical and Translational Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Translational Research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The dietary supplement Cyplexinol® alleviates joint pain in men and women.
Background and aim: Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study.
Methods: We compared the impact of a dietary supplement protein complex (Cyplexinol®) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures.
Results: Pain and discomfort scores improved (P ≤ 0.05) for subjects following use of Cyplexinol® but not placebo. Improvements were noted for WOMAC pain (P = 0.05), stiffness (P = 0.039), and total pain (P = 0.026), as well as VAS pain (P = 0.015), recreational activity interference (P = 0.023), mood interference (P = 0.012), and total pain (P = 0.024). A trend was noted for WOMAC physical function (P = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol® (P = 0.01), with a similar increase noted for placebo (P = 0.022). A near doubling in TGF-β (P = 0.001) was noted for Cyplexinol®. No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (P > 0.05).
Conclusions: Cyplexinol® can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol® does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period.
Relevance for patients: Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol®, as we observed decreased pain and stiffness following treatment.